Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) develops RNA interference medicines designed to silence genes associated with disease, using its proprietary TRiM delivery platform and a range of RNA chemistries. Its products and investigational candidates target conditions including lipid disorders, liver and kidney… From the company’s description.
Over the twelve months to Jun 30, 2026, Arrowhead Pharmaceuticals, Inc. reported revenue of $669.50M, up 16.8% from a year earlier, and a net loss of $272.13M. Its operating margin was −33.8%, and operations used $59.05M in cash. In fiscal 2025, it reported revenue of $829.45M, up 23258.2% from fiscal 2024, and net income of $30.11M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arrowhead Pharmaceuticals, Inc. does
In the company’s own words
Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) develops RNA interference medicines designed to silence genes associated with disease, using its proprietary TRiM delivery platform and a range of RNA chemistries. Its products and investigational candidates target conditions including lipid disorders, liver and kidney diseases, obesity, neurological disorders, and genetic muscle diseases. The company’s first approved medicine, REDEMPLO (plozasiran), treats adults with familial chylomicronemia syndrome; its broader pipeline includes clinical-stage programs developed by Arrowhead and through collaborations with pharmaceutical companies such as Sarepta, Takeda, Amgen, GSK, and Novartis. Arrowhead licenses or co-develops certain programs with partners, while retaining programs it plans to commercialize itself. The company reports 18 discovered drug candidates in clinical trials, from Phase 1 through Phase 3, and launched REDEMPLO in 2025. Its present business builds on RNAi assets acquired from Novartis in 2015 and Roche’s RNAi therapeutics business in 2011. Its website is www.arrowheadpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PASADENA, CA
- Fiscal year end
- September
- CIK
- 879407
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arrowhead Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Arrowhead Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Arrowhead Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Arrowhead Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Arrowhead Pharmaceuticals, Inc.’s debt, $93.19M at market value — what funds hold, not the company’s total debt.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arrowhead Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arrowhead Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arrowhead Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”